After more than 70 years of successful brand history, vwd, as a leading provider of Europe-wide information and IT solutions for the investment industry, will continue to operate under the Infront brand. In July 2019 it was already announced that vwd was acquired by Infront ASA. Since then, the integration of vwd has progressed fast. On 28 February 2020, the renaming of vwd Vereinigte Wirtschaftsdienste GmbH to Infront Financial Technology GmbH...
London, Infront (INFRT) announced today that the Infront Professional Terminal has been chosen by the University College Birmingham in England for their new trading suite. It is the first university trading suite to be powered by Infront, with 21 Infront Professional Terminals in place, offering unique benefits for students.
The event was cancelled.
The BVI Fund Operations Conference will inform you about the trends in the securities and fund industry on 31 March 2020 in Cape Europe - with more than 40 presentations in parallel tracks.
In addition, you can expect interesting presentations on topics such as sustainability, digitization, information security, financial market data, trading, regulatory and investor reporting, real estate management and custodian issues.
Further information about the event can be found here...
This event has been cancelled.
When great people and great companies come together, amazing potential can be realized. Join the Tech Job Fair! Update your resume, and get ready for an interview with us. Here you'll find our current vacancies.
23.04.2020, 18.00 - 21.00
Software Improvement Group
Fred. Roeskestraat 115
Amsterdam, 1076 EE Netherlands
Every year more than 11,000 students use konaktiva to get closer to an internship, a working student position and even their dream job.
Come by and get to know us! You are also welcome to make an appointment with us in advance. Please contact Stefanie Blasi by mail.
12. May 2020, 09:30 - 16:30 o'clock
darmstadtium (Science and Congress Centre), Schloßgraben 1, 64283 Darmstadt, Germany
Students of all disciplines and universities
Visiting the fair is free of charge and does not require registration. The konaktiva is organised by a team of volunteer students.
This event has been cancelled.
Motivated graduates and students of all disciplines from universities and universities of applied sciences from all over southwest Germany have the opportunity to get to know what we have to offer and make their first contacts at the meeting point company contact fair in Kaiserslautern.
You will find us from 10.00 to 16.00 in building 42 of the TU Kaiserslautern. You are also welcome to arrange an appointment with us in advance. Please send an e-mail to Sandra Schintu.
We will again be represented at the DKF this year and look forward to your visit to our stand.
Further information will be available here soon or on the official DKF 2020 website.
The EMEA Trading Conferenceis Europe’s largest one-day electronic trading event. The event will cover the most pressing issues facing the institutional trading community and provide a neutral platform for buy-side, sell-side, exchanges, vendors and regulators to share their ideas on how the community can continue to collaborate. Designed to appeal to all asset classes, the agenda will maintain a great balance of topics across multiple asset classes.
As in previous years, COPS invites to their annual COPS user meeting this year from 22 to 23 October 2020 at the Seehotel Rust in Rust on Neusiedlersee.
The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.
As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.
You can find further information here...
The SIPUGday focuses since the start on market data and related technologies, services and products in the front, back and middle office. Regulations and their impact on data are also a topic for our audience.
Infront and vwd will be represented on site by Ivo Bieri, Managing Director Switzerland. He will be happy to inform you about the advantages for you of the merger of the two companies in the future. We look forward to a lively exchange with you!
October 27, 2020
26.03.2020 BUSINESS WIRE: Ipsen Provides Update on Palovarotene Clinical Programs
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
Ipsen to reinitiate palovarotene dosing in patients 14 years of age and older with fibrodysplasia ossificans progressiva
Ipsen to terminate MO-Ped trial (PVO-2A-201) in patients with multiple osteochondromas to analyze accumulated data and assess the future of palovarotene in this indication
PARIS --(BUSINESS WIRE)-- 26.03.2020 --
Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will begin to reinitiate palovarotene dosing in patients 14 years of age and older currently participating in its fibrodysplasia ossificans progressiva (FOP) clinical program. The Food and Drug Administration (FDA) in the U.S. has confirmed they have no safety concerns with restarting dosing in patients 14 years of age and older. Clearance to reinitiate dosing in these patients has also been received to date from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, the National Agency for the Safety of Medicines and Health Products Safety (ANSM) in France, the Medical Products Agency (MPA) in Sweden, the Italian Medicines Agency (AIFA), the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina, the Spanish Agency of Medicines and Medical Devices (AEMPS), and Health Canada (HC).
The decision to pause dosing of palovarotene in the global Phase III MOVE trial (PVO-1A-301), as well as the ongoing Phase II (PVO-1A-202/204) extension studies in FOP was made by Ipsen on 24 January 2020, based on results of a futility analysis as part of the pre-specified interim analysis.
Encouraging therapeutic activity was observed in preliminary post-hoc analyses of interim data for the Phase III MOVE trial and shared with, and acknowledged by, the Independent Data Monitoring Committee (IDMC). As such, the company amended the protocol for the Phase III MOVE trial to include updates to the statistical analysis section as recommended by the IDMC to allow for additional analyses to be performed in addition to the primary pre-specified analysis. The protocol amendments are based on the IDMC’s observation that the protocol pre-specified statistical model may have negatively affected the efficacy analysis and shifted the statistical conclusion from significant therapeutic benefit to showing futility of the treatment.
“We are pleased that Ipsen has received the approval to reinitiate dosing in patients 14 years of age and older in the Phase III MOVE trial from several regulatory agencies to date following review of the additional data. After consultation with patient groups and investigators, we have been working diligently with all relevant stakeholders to restart the trial as quickly as possible,” said Dr. Howard Mayer, Executive Vice President and Head of Research and Development at Ipsen. “We remain committed to bringing palovarotene to patients living with this devastating disease and will continue our conversations with the health authorities to determine the most appropriate regulatory path forward.”
Ipsen is now working to obtain the approvals from the ethics committee (EC) of each clinical site and, upon receipt of both regulatory approval where required and EC approval, the reinitiation of dosing may begin. At this point, physicians or trial coordinators will contact eligible patients to share more details and advise on appropriate steps for the reinitiation of treatment. Appropriate measures will also be taken to ensure the safety of FOP patients who restart dosing in light of the ongoing COVID-19 pandemic, taking into consideration local regulatory and health authority guidance, as well as the ability of individual investigators and sites to adequately monitor patient safety.
The FDA partial clinical hold issued on 4 December 2019 for the pediatric population under the age of 14 for FOP and multiple osteochondroma (MO) studies remains in effect. In relation to this, Ipsen is currently addressing the questions from the FDA and other health authorities to expeditiously establish a course of action for FOP studies for the pediatric population under the age of 14.
Ipsen is also addressing the partial clinical hold questions from the FDA related to the MO program. However, Ipsen has taken the decision to terminate its MO-Ped trial (PVO-2A-201) conducted under IND135403 to analyze the accumulated data to better inform on the efficacy, safety and future of palovarotene in MO, and to potentially establish a path forward for palovarotene in this indication, including an assessment as to the potential for an NDA submission to the FDA. Ipsen believes however that an NDA submission for the treatment of MO based on the MO-Ped trial (PVO-2A-201) conducted under IND135403 is highly unlikely. The reasons for Ipsen’s decision include the time that the partial clinical hold has been in place leading to a significant gap in dosing which may compromise the integrity of the data, that the trial was not fully enrolled at the time the partial clinical hold was instituted (as such, very few patients had reached the trial midpoint), and there is no efficacy data available in this patient population currently to further inform a benefit/risk assessment.
About the FOP clinical program
The Phase III MOVE (PVO-1A-301) trial is an open-label, single-arm, efficacy and safety trial evaluating a chronic/episodic dosing regimen of palovarotene which includes a 5 mg daily dose of palovarotene in addition to the episodic 20/10 mg dosing regimen following any flare-ups (note that doses are weight-adjusted). The trial is being conducted in the U.S., Argentina, Australia, Brazil, Canada, France, Italy, Japan, Spain, Sweden and the United Kingdom. There are two ongoing Phase II (PVO-1A-202/204) extension studies; 1) Study 202 an open-label extension of Study 201, the initial Phase II randomized, double-blind, multi-center trial, and 2) Study 204 an open-label study corresponding to PVO-1A-202 to evaluate the safety and efficacy of different palovarotene dosing regimens in subjects with FOP in France.
Palovarotene is a RARγ agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene, which had rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder, was acquired by Ipsen through the acquisition in April 2019 of Clementia Pharmaceuticals.
About fibrodysplasia ossificans progressiva (FOP)
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, severely disabling disorder characterized by bone that forms outside the normal skeleton, in muscles, tendons or soft tissue.1 FOP is among the rarest of human diseases, and while there are approximately 1,000 confirmed cases globally, the prevalence of FOP is estimated at approximately 1.36 per million individuals.2,3
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
Ipsen—Cautionary Note Regarding Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons and also taking into consideration assessment delays of certain clinical trials in light of the ongoing COVID-19 pandemic. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2018 Registration Document available on its website (www.ipsen.com).
Christian Marcoux, M.Sc.
Senior Vice President, Global Communications
+33 (0)1 58 33 67 94
Senior Director, France Hub, Global Communications
+33 (0) 1 58 33 58 96
Vice President, Investor Relations
+44 (0) 1753 627721
Investor Relations Manager
+33 (0)1 58 33 51 04
27.03.2020 Mynewsdesk: DACHSER stellt Vorstand für die Zukunft auf
Bernhard Simon, CEO, und sein Stellvertreter Michael Schilling, COO Road Logistics, werden nach 31 Jahren der engen Zusammenarbeit in operativen Führungspositionen bei DACHSER 2021 gemeinsam in den Verwaltungsrat des Logistikdienstleisters eintreten. Bernhard Simon wird dann den Vorsitz des ...
27.03.2020 Mynewsdesk: Sicherheit und Diskretion für die Geschäftswelt: Mit der jenID-Lösung online Verträge abschließen
Die Online-Lösung zur Überprüfung von Ausweisdokumenten der jenID Solutions GmbH: https://www.jenidsolutions.com/de/ kann dabei helfen, B2B-Vertragsabschlüsse über das Netz diskret und sicher zu gestalten. jenID setzt dazu auf maschinelles Lernen und fortschrittliche ...
27.03.2020 Mynewsdesk: Rechtzeitig Liquidität sichern: First Debit macht titulierte Forderungen jetzt zu Geld
Hamm, im März 2020 - Von der Corona-Krise ist fast jeder mehr oder weniger betroffen, die wirtschaftlichen Auswirkungen auf viele Branchen sind noch gar nicht absehbar. Nie war Liquidität wichtiger als in diesen außergewöhnlichen Zeiten. Aber abgesagte Gerichtstermine und ...
27.03.2020 Mynewsdesk: SYZYGY bestätigt vorläufige Zahlen: Umsatzerlöse von EUR 64,2 Mio. - Dividendenvorschlag in Höhe von EUR 0,20
- Konzernumsatz EUR 64,2 Mio. (-2 Prozent ggü. Vorjahr)- Operatives Ergebnis EUR 5,5 Mio. (-9 Prozent ggü. Vorjahr)- Konzernergebnis EUR 4,2 Mio. (-17 Prozent ggü. Vorjahr)- Dividendenvorschlag in Höhe von EUR 0,20- Ausblick 2020: Umsatzrückgang um 10 bis 20 Prozent und ...
27.03.2020 Mynewsdesk: Business Continuity in Krisenzeiten: Crealog Mobile Call Recording unterstützt die Finanzbranche in der Corona-Pandemie
München, im März 2020 - Die Corona-Krise trifft nahezu alle Branchen mit voller Wucht, die wirtschaftlichenFolgen sind kaum absehbar. Auch Banken, Finanzdienstleister, Kreditinstitute und Versicherungen haben ihre Mitarbeiter inzwischen zum Großteil ins Home-Office geschickt, wo sie ...
27.03.2020 Mynewsdesk: Privater Unfallschutz im Home Office essentiell
Im Zuge der aktuellen Situation steigt der Anteil derjenigen Menschen, die von zu Hause aus arbeiten. Sie sind während ihrer Arbeitszeit grundsätzlich gesetzlich unfallversichert. Aufgrund der Überschneidung von privater und beruflicher Sphäre ist aber eine private ...
26.03.2020 GlobeNewswire: GENERALVERSAMMLUNG 2020 DER SIKA AG
GENERALVERSAMMLUNG 2020 DER SIKA AG GENERALVERSAMMLUNG 2020 DER SIKA AG Verwaltungsrat bestätigt 21. April 2020 als Termin für die Generalversammlung Gestützt auf die vom Bundesrat erlassene Verordnung über die Massnahmen zur Bekämpfung des Coronavirus können Aktionäre nicht persönlich an der Generalversammlung teilnehmen Alle...
26.03.2020 GlobeNewswire: VISTAJET UNTERSTÜTZT REGIERUNGEN UND MEDIZINISCHE ORGANISATIONEN WÄHREND DER KRISE MIT GLOBALER INFRASTRUKTUR
VISTAJET UNTERSTÜTZT REGIERUNGEN UND MEDIZINISCHE ORGANISATIONEN WÄHREND DER KRISE MIT GLOBALER INFRASTRUKTUR Unterstützung für Gemeinschaften und Einzelpersonen VistaJet bietet kostenlose Leerflüge für Regierungen und den Transport medizinischer Ressourcen an; Globale Infrastruktur und Fachwissen für den Transport wichtiger...
26.03.2020 GlobeNewswire: Veränderung in der Konzernleitung von Tecan
Veränderung in der Konzernleitung von Tecan Männedorf, Schweiz, 26. März 2020 – Die Tecan Group (SIX Swiss Exchange: TECN) hat heute bekannt gegeben, dass Markus Schmid, seit 2011 Head of Corporate Human Resources & Internal Communications sowie Mitglied der Konzernleitung, das Unternehmen verlassen wird. Sein Austritt aus dem...
26.03.2020 GlobeNewswire: Medienmitteilung | MCH Group | Ergebnis 2019
Medienmitteilung | MCH Group | Ergebnis 2019 MCH Group: Deutliche Ergebnis-Verbesserung im Geschäftsjahr 2019 Trotz Umsatzrückgang klare Steigerung des EBITDA Starke Einbussen durch Coronakrise, aber keine Gefährdung der Unternehmensgruppe Strategieumsetzung und Prüfung der Finanzierungsoptionen werden intensiv vorangetrieben...
25.03.2020 GlobeNewswire: ZAGENO veröffentlicht Daten zu den Auswirkungen von COVID-19 auf die Laborlieferkette
ZAGENO veröffentlicht Daten zu den Auswirkungen von COVID-19 auf die Laborlieferkette Trends zeigen die Auswirkungen der Pandemie auf Lieferanten und Kunden im Life-Science-Bereich Cambridge, Massachusetts, und Berlin, March 25, 2020 (GLOBE NEWSWIRE) -- ZAGENO, eine führender e-Commerce-Plattform für Life-Science-Produkte, hat...
25.03.2020 GlobeNewswire: Euro Manganese kündigt Privatplatzierung in Höhe von 1 Million CAD an
Euro Manganese kündigt Privatplatzierung in Höhe von 1 Million CAD an NICHT ZUR VERTEILUNG AN NACHRICHTENAGENTUREN DER VEREINIGTEN STAATEN ODER ZUR VERBREITUNG IN DEN VEREINIGTEN STAATEN VANCOUVER, British Columbia, March 25, 2020 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V/ASX: EMN) (das „ Unternehmen “ oder „ EMN “) freut...